Join Dr. Fatima Cody Stanford, Dr. Richard Frank, and Veeneta Lakhani as they break down what toda’ys evolving treatment landscape means for benefit leaders, payers, and consultants.
– How GLP-1s and other lower-cost obesity medications work to a surprising effect
– What new clinical indications mean for coverage and access
– Scalable care models that combine medical, behavioral, and digital support
– How to balance innovation and cost-effectiveness
Obesity isn’t a willpower problem, and it never was.
Obesity is a growing health concern and many still face significant barriers to accessing obesity care. Employers who invest in providing obesity care can foster a healthier, more engaged workforce, while reducing healthcare costs.
Join Dr. Fatima Cody Stanford, Dr. Richard Frank, and Veeneta Lakhani as they break down what toda’ys evolving treatment landscape means for benefit leaders, payers, and consultants.